In cancer patients, systemic EGFR inhibition is associated with several cutaneous side effects, including aberrant keratinocyte differentiation and skin barrier impairment (Gisondi et al., 2021[21]; Lacouture, 2006[47]). The gene discussed is EGFR; the disease is cancer.